Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

ABT‐089 and ABT‐894 reduce levodopa‐induced dyskinesias in a monkey model of Parkinson's disease
Danhui Zhang, Tanuja Bordia, Matthew McGregor, et al.
Movement Disorders (2014) Vol. 29, Iss. 4, pp. 508-517
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Matthieu F. Bastide, Wassilios G. Meissner, Barbara Picconi, et al.
Progress in Neurobiology (2015) Vol. 132, pp. 96-168
Open Access | Times Cited: 430
Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson’s disease
Santiago Perez‐Lloret, Francisco J. Barrantes
npj Parkinson s Disease (2016) Vol. 2, Iss. 1
Open Access | Times Cited: 185
Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies
Destany K. Kwon, Mohit Kwatra, Jing Wang, et al.
Cells (2022) Vol. 11, Iss. 23, pp. 3736-3736
Open Access | Times Cited: 78
Cholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditions
Kalynda K. Gonzales, Yoland Smith
Annals of the New York Academy of Sciences (2015) Vol. 1349, Iss. 1, pp. 1-45
Open Access | Times Cited: 145
Alpha7 nicotinic receptors as therapeutic targets for Parkinson's disease
Maryka Quik, Danhui Zhang, Matthew McGregor, et al.
Biochemical Pharmacology (2015) Vol. 97, Iss. 4, pp. 399-407
Open Access | Times Cited: 109
The nicotinic α6 subunit gene determines variability in chronic pain sensitivity via cross-inhibition of P2X2/3 receptors
Jeffrey S. Wieskopf, Jayanti Mathur, Walrati Limapichat, et al.
Science Translational Medicine (2015) Vol. 7, Iss. 287
Open Access | Times Cited: 106
Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson’s disease
George E. Barreto, Alexandre Iarkov, Valentina Echeverrı́a
Frontiers in Aging Neuroscience (2015) Vol. 6
Open Access | Times Cited: 103
Nicotine from cigarette smoking and diet and Parkinson disease: a review
Chaoran Ma, Yesong Liu, Samantha Neumann, et al.
Translational Neurodegeneration (2017) Vol. 6, Iss. 1
Open Access | Times Cited: 100
Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias
Tanuja Bordia, Xiomara A. Perez, Jaime E. Heiss, et al.
Neurobiology of Disease (2016) Vol. 91, pp. 47-58
Open Access | Times Cited: 74
Nicotinic Acetylcholine Receptor Dysfunction in Addiction and in Some Neurodegenerative and Neuropsychiatric Diseases
Ana Sofía Vallés, Francisco J. Barrantes
Cells (2023) Vol. 12, Iss. 16, pp. 2051-2051
Open Access | Times Cited: 19
Nicotine and Nicotinic Receptor Drugs
Maryka Quik, Tanuja Bordia, Danhui Zhang, et al.
International review of neurobiology (2015), pp. 247-271
Closed Access | Times Cited: 63
Role for the nicotinic cholinergic system in movement disorders; therapeutic implications
Maryka Quik, Danhui Zhang, Xiomara A. Perez, et al.
Pharmacology & Therapeutics (2014) Vol. 144, Iss. 1, pp. 50-59
Open Access | Times Cited: 56
Pathophysiological Mechanisms and Experimental Pharmacotherapy for L-Dopa-Induced Dyskinesia
A Fabbrini, Andrea Guerra
Journal of Experimental Pharmacology (2021) Vol. Volume 13, pp. 469-485
Open Access | Times Cited: 37
Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease
Eva Schaeffer, Andrea Pilotto, Daniela Berg
CNS Drugs (2014) Vol. 28, Iss. 12, pp. 1155-1184
Closed Access | Times Cited: 51
Dystonia and levodopa-induced dyskinesias in Parkinson's disease: Is there a connection?
Paolo Calabresi, David G. Standaert
Neurobiology of Disease (2019) Vol. 132, pp. 104579-104579
Open Access | Times Cited: 36
Nicotine-mediated effects in neuronal and mouse models of synucleinopathy
Mohamed Bilal Fares, Omar Alijevic, Stéphanie Johne, et al.
Frontiers in Neuroscience (2023) Vol. 17
Open Access | Times Cited: 12
The Role of α7-Nicotinic Acetylcholine Receptors in the Pathophysiology and Treatment of Parkinson’s Disease
Eslam El Nebrisi, Yosra Lozon, Murat Öz
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 3210-3210
Open Access
A new outlook on cholinergic interneurons in Parkinson’s disease and L-DOPA-induced dyskinesia
Melissa M. Conti, Nicole Chambers, Christopher Bishop
Neuroscience & Biobehavioral Reviews (2018) Vol. 92, pp. 67-82
Closed Access | Times Cited: 34
Predictive Value of Parkinsonian Primates in Pharmacologic Studies: A Comparison between the Macaque, Marmoset, and Squirrel Monkey
Nicolas Veyres, Adjia Hamadjida, Philippe Huot
Journal of Pharmacology and Experimental Therapeutics (2018) Vol. 365, Iss. 2, pp. 379-397
Open Access | Times Cited: 33
Using artificial intelligence to identify drugs for repurposing to treat l-DOPA-induced dyskinesia
Tom H. Johnston, Alix M.B. Lacoste, Paula Ravenscroft, et al.
Neuropharmacology (2024) Vol. 248, pp. 109880-109880
Open Access | Times Cited: 3
The α7 Nicotinic Receptor Agonist ABT-107 Decreases l-Dopa–Induced Dyskinesias in Parkinsonian Monkeys
Danhui Zhang, Matthew McGregor, Michael Decker, et al.
Journal of Pharmacology and Experimental Therapeutics (2014) Vol. 351, Iss. 1, pp. 25-32
Open Access | Times Cited: 33
Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders
Maryka Quik, James T. Boyd, Tanuja Bordia, et al.
Nicotine & Tobacco Research (2018) Vol. 21, Iss. 3, pp. 357-369
Open Access | Times Cited: 32
Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease
Fabio Del Bello, Mario Giannella, Gianfabio Giorgioni, et al.
Biomolecules (2019) Vol. 9, Iss. 4, pp. 142-142
Open Access | Times Cited: 29
α6-Containing nicotinic acetylcholine receptors in midbrain dopamine neurons are poised to govern dopamine-mediated behaviors and synaptic plasticity
Jennifer N. Berry, Staci E. Engle, J. M. McIntosh, et al.
Neuroscience (2015) Vol. 304, pp. 161-175
Open Access | Times Cited: 27
The use of nonhuman primate models to understand processes in Parkinson’s disease
Javier Blesa, Inés Trigo‐Damas, Natalia López‐González del Rey, et al.
Journal of Neural Transmission (2017) Vol. 125, Iss. 3, pp. 325-335
Closed Access | Times Cited: 27
Page 1 - Next Page

Scroll to top